ZLAB
Zai Lab Limited · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 40 | -10 | 13.04M | $247.56M | +1 | −11 |
| Q1 2026 | 51 | -8 | 9.02M | $169.34M | +7 | −15 |
| Q4 2025 | 58 | 0 | 14.32M | $252.66M | +1 | −1 |
| Q3 2025 | 13 | -2 | 15.41M | $522.27M | — | −2 |
| Q2 2025 | 12 | -2 | 15.57M | $544.48M | — | −2 |
| Q1 2025 | 12 | 0 | 13.16M | $475.75M | — | — |
| Q4 2024 | 12 | 0 | 16.81M | $440.22M | +1 | −1 |
| Q3 2024 | 11 | +1 | 20.32M | $490.64M | +1 | — |
| Q2 2024 | 10 | — | 17.23M | $298.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 7.12M | — | $123.47M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Capital World Investors ✦ | 5.31M | — | $91.99M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Viking Global Investors ✦ | 2.04M | — | $35.31M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 1.66M | — | $28.73M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 1.66M | — | $28.73M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 899.67K | — | $15.59M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 899.67K | — | $15.59M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 65.89K | — | $1.14M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Millennium Management ✦ | 53.37K | — | $924,867 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passive) | 34.52K | — | $598,214 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 28.21K | — | $488,949 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 17.41K | — | $301,663 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 97 holders, 28.24M shares, $515.77M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 260 sh · $7,020
Director · 8.51K sh · $212,650
Officer · 619 sh · $15,475
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology